Correction: Safety and feasibility of intravenous administration of a single dose of allogenic-Muse cells to treat human cervical traumatic spinal cord injury: a clinical trial.
Koda M, Imagama S, Nakashima H, Ito S, Segi N, Ouchida J, Suda K, Harmon Matsumoto S, Komatsu M, Endo T, Suzuki S, Inami S, Ueda H, Miyagi M, Inoue G, Takaso M, Nagata K, Yamada H, Kamei N, Nakamae T, Suzuki H, Nishida N, Funaba M, Kumagai G, Furuya T, Yamato Y, Funayama T, Takahashi H, Yamazaki M.
Koda M, et al. Among authors: yamazaki m.
Stem Cell Res Ther. 2024 Nov 6;15(1):402. doi: 10.1186/s13287-024-04044-0.
Stem Cell Res Ther. 2024.
PMID: 39506800
Free article.
No abstract available.